Skip to content
10-Q

Quarterly Report

Horizon Therapeutics Public Ltd Co

0000950170-23-016886

← back to feed
Filed
May 3, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Apr 27, 2023 228.62M sh
Shares Diluted Q1 2023 · Mar 31, 2023 233.79M sh
Shares Diluted Q1 2023 · Mar 31, 2022 235.95M sh
Capex Q1 2023 · Mar 31, 2023 $24.13M
Capex Q1 2023 · Mar 31, 2022 $14.2M
Operating Cash Flow Q1 2023 · Mar 31, 2023 $86.32M
Operating Cash Flow Q1 2023 · Mar 31, 2022 $215.79M
Long Term Debt Q1 2023 · Mar 31, 2023 $2.54B
Long Term Debt Q1 2023 · Dec 31, 2022 $2.55B
Short Term Debt Q1 2023 · Mar 31, 2023 $16M
Short Term Debt Q1 2023 · Dec 31, 2022 $16M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $2.31B
Cash And Equivalents Q1 2023 · Dec 31, 2022 $2.35B
Stockholders Equity Q1 2023 · Mar 31, 2023 $5.1B
Stockholders Equity Q1 2023 · Dec 31, 2022 $5.07B
Stockholders Equity Q1 2023 · Mar 31, 2022 $4.82B
Stockholders Equity Q1 2023 · Dec 31, 2021 $4.67B
Current Liabilities Q1 2023 · Mar 31, 2023 $884.89M
Current Liabilities Q1 2023 · Dec 31, 2022 $949.14M
Current Assets Q1 2023 · Mar 31, 2023 $3.6B
Current Assets Q1 2023 · Dec 31, 2022 $3.65B
Total Assets Q1 2023 · Mar 31, 2023 $8.99B
Total Assets Q1 2023 · Dec 31, 2022 $9.11B
Eps Diluted Q1 2023 · Mar 31, 2023 $0.23
Eps Diluted Q1 2023 · Mar 31, 2022 $0.87
Eps Basic Q1 2023 · Mar 31, 2023 $0.24
Eps Basic Q1 2023 · Mar 31, 2022 $0.89
Sga Expense Q1 2023 · Mar 31, 2023 $453.35M
Sga Expense Q1 2023 · Mar 31, 2022 $372.73M
Rd Expense Q1 2023 · Mar 31, 2023 $134.15M
Rd Expense Q1 2023 · Mar 31, 2022 $103.13M
Net Income Q1 2023 · Mar 31, 2023 $54.68M
Net Income Q1 2023 · Mar 31, 2022 $204.26M
Operating Income Q1 2023 · Mar 31, 2023 $35.99M
Operating Income Q1 2023 · Mar 31, 2022 $194.32M
Gross Profit Q1 2023 · Mar 31, 2023 $623.5M
Gross Profit Q1 2023 · Mar 31, 2022 $670.18M
Cost Of Revenue Q1 2023 · Mar 31, 2023 $208.56M
Cost Of Revenue Q1 2023 · Mar 31, 2022 $215.06M
Revenue Q1 2023 · Mar 31, 2023 $832.06M
Revenue Q1 2023 · Mar 31, 2022 $885.25M